Contact lens products

Abstract

A contact lens product comprises a contact lens and a buffer solution. The contact lens is stored in the buffer solution. The buffer solution comprises at least one antioxidant. The contact lens comprises at least one curcumin derivative. Thus, the contact lens can efficiently absorb high-energy ultraviolet light or blue light in the environment and convert it into weak-energy light, which can effectively protect the retina and reduce damage.

Description

Technical Field

[0001] The present invention relates to a contact lens product, and in particular to a contact lens product which helps to reduce stray light and eliminate glare. Background Art

[0002] In order to protect the eyes from damage caused by strong energy light, contact lenses generally use chemically synthesized ultraviolet light / blue light absorbers to achieve a blocking effect. However, traditional light absorbers can easily cause discomfort when in contact with the eyes. Excessive doses may even cause serious immune reactions or toxic damage to the eyes. However, curcumin (curcumin, (1E, 6E)-1,7-Bis (4-hydroxy-3-methoxyphenyl) -1,6-heptadiene-3,5-dione) generally cannot form a good bonding effect with contact lens monomers, resulting in easy release from contact lenses, and even unable to overcome the high temperature and high pressure sterilization process and lead to decomposition. Summary of the invention

[0003] According to the present invention, a contact lens product is provided, comprising a contact lens and a buffer solution. The contact lens is stored in the buffer solution, wherein the buffer solution contains at least one antioxidant. The contact lens contains at least one curcumin derivative, wherein the curcumin derivative has a structure as shown in formula (I) or formula (II):

[0004]

[0005] Where R 1 With R 2 At least one of them is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylate-2,3-dihydroxypropyl ester and hydrogen, and R 1 With R 2 are not simultaneously hydrogen; or

[0006]

[0007] Where R 3 With R 4 At least one of them is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylate-2,3-dihydroxypropyl ester and hydrogen, R 5 is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid and 2-methyl-2-acrylate-2,3-dihydroxypropyl ester, and R 3 With R 4 Wherein, the weight percentage concentration of the curcumin derivative in the contact lens is Ccu, and the weight percentage concentration of the antioxidant in the buffer solution is Cao, which satisfies the following conditions:

[0008] 0.01≤Ccu / Cao≤10.00.

[0009] Thus, the contact lens product of the present invention is designed to include a novel curcumin derivative with high monomer bonding efficiency obtained by modifying natural curcumin, and the curcumin derivative of the present invention has the effect of absorbing light and changing color quickly, which helps to efficiently absorb high-energy ultraviolet light or blue light in the environment and convert it into weak energy light, which can effectively protect the retina and reduce damage. Furthermore, the contact lens product of the present invention is further designed to have an appropriate concentration of antioxidants to overcome the problem that the stability of the curcumin derivative is destroyed by high-temperature and high-pressure sterilization of the contact lens product, and the optimal antioxidant concentration combination in the buffer solution can effectively stabilize and prolong the absorption effect of the curcumin derivative of the present invention, so as to fully exert the anti-glare protection effect of the contact lens. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] In order to make the above and other objects, features, advantages and embodiments of the present invention more clearly understood, the accompanying drawings are described as follows:

[0011] Figure 1 is a schematic diagram illustrating a contact lens product according to one embodiment of the present invention;

[0012] Figure 2 It is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 280nm to 310nm;

[0013] Figure 3 It is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 310nm to 380nm;

[0014] Figure 4 It is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 410nm to 460nm;

[0015] Figure 5 It is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 460nm to 780nm;

[0016] Figure 6 It is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 380nm to 780nm;

[0017] Figure 7 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 280nm to 310nm;

[0018] Figure 8is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 310nm to 380nm;

[0019] Fig. 9 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 410nm to 460nm;

[0020] Fig.10 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 460nm to 780nm; and

[0021] Fig.11 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 380nm to 780nm;

[0022] Among them, the symbols are as follows:

[0023] 100: Contact lens products

[0024] 110: Contact lenses

[0025] 120: Buffer solution. DETAILED DESCRIPTION

[0026] Please refer to Figure 1 , which is a schematic diagram of a contact lens product 100 according to one embodiment of the present invention. The contact lens product 100 includes a contact lens 110 and a buffer solution 120. The contact lens 110 is stored in the buffer solution 120, and the buffer solution 120 includes at least one antioxidant.

[0027] The contact lens 110 comprises at least one curcuminoid derivative, wherein the curcumin derivative has a structure as shown in formula (I) or formula (II):

[0028]

[0029] Where R 1 With R 2 At least one of the above is selected from the group consisting of 2-Hydroxyethylmethacrylate (HEMA), methacrylic acid (MAA), 2-methyl-2-acrylate-2,3-dihydroxypropyl ester (GMA) and hydrogen (H), and R 1 With R 2 are not simultaneously hydrogen; or

[0030]

[0031] Where R 3 With R 4 At least one of them is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylate-2,3-dihydroxypropyl ester and hydrogen, R 5 is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid and 2-methyl-2-acrylate-2,3-dihydroxypropyl ester, and R 3 With R 4 Not hydrogen at the same time.

[0032] In the contact lens product 100 of the present invention, the weight percentage concentration of the curcumin derivative in the contact lens 110 is Ccu, and the weight percentage concentration of the antioxidant in the buffer solution 120 is Cao, which satisfies the following conditions: 0.01≤Ccu / Cao≤10.00. Alternatively, it may satisfy the following conditions: 0.02≤Ccu / Cao≤8.00. Alternatively, it may satisfy the following conditions: 0.03≤Ccu / Cao≤3.00. Alternatively, it may satisfy the following conditions: 0.04≤Ccu / Cao≤1.00. Alternatively, it may satisfy the following conditions: 0.05≤Ccu / Cao≤0.70.

[0033] Thus, the contact lens 110 of the contact lens product 100 of the present invention is designed to include at least one novel curcumin derivative with high monomer bonding efficiency obtained by modifying natural curcumin, and the curcumin derivative of the present invention has the effect of absorbing light and changing color quickly, which helps to efficiently absorb high-energy ultraviolet light or blue light in the environment and convert it into weak energy light, which can effectively protect the retina and reduce damage. Furthermore, the contact lens product 100 of the present invention is further designed to have an appropriate concentration of antioxidants to overcome the problem that the contact lens product 100 is sterilized at high temperature and high pressure and destroys the stability of the curcumin derivative, and the optimal antioxidant concentration combination in the buffer solution 120 can effectively stabilize and prolong the absorption effect of the curcumin derivative of the present invention, so as to fully exert the anti-glare protection effect of the contact lens 110. Furthermore, the curcumin derivative of the contact lens 110 of the present invention can also be mixed with colorants to achieve the desired color change, and then applied to multifocal contact lenses that can reduce and control vision, so that it can help reduce stray light to eliminate glare, and by adjusting the appropriate concentration, it can block strong light to achieve an efficient shading effect, but the present invention is not limited to this.

[0034] In the contact lens product 100 of the present invention, R of the curcumin derivative of formula (I) 1 With R 2 At least one of them may be hydroxyethyl methacrylate, and R of the curcumin derivative of formula (II) 3 With R 4At least one of the monomers may be hydroxyethyl methacrylate. Thus, the compatibility of the curcumin derivative in the manufacture of the contact lens 110 can be increased, so that the monomer material can be directly bonded with the curcumin derivative with good monomer bonding efficiency.

[0035] In the contact lens product 100 of the present invention, R of the curcumin derivative of formula (II) 5 It can be methacrylic acid or 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester. Thus, it can have a better monomer bonding efficiency, which helps to improve the bonding compatibility between the curcumin derivative and the monomer material.

[0036] In the contact lens product 100 of the present invention, the weight percentage concentration of the curcumin derivative in the contact lens 110 is Ccu, which can satisfy the following conditions: 0.01% ≤ Ccu ≤ 5.00%. Thereby, the high energy wavelength absorption effect of the contact lens 110 containing the curcumin derivative of the present invention can be effectively prolonged. Alternatively, it can satisfy the following conditions: 0.02% ≤ Ccu ≤ 4.00%. Alternatively, it can satisfy the following conditions: 0.03% ≤ Ccu ≤ 3.00%. Alternatively, it can satisfy the following conditions: 0.04% ≤ Ccu ≤ 2.00%. Alternatively, it can satisfy the following conditions: 0.04% ≤ Ccu ≤ 1.00%.

[0037] In the contact lens product 100 of the present invention, the weight percentage concentration of the antioxidant in the buffer solution 120 is Cao, which can meet the following conditions: 0.05% ≤ Cao ≤ 5.00%. Thereby, the high energy wavelength absorption effect of the contact lens 110 containing the curcumin derivative of the present invention can be effectively prolonged. Alternatively, it can meet the following conditions: 0.06% ≤ Cao ≤ 4.00%. Alternatively, it can meet the following conditions: 0.07% ≤ Cao ≤ 3.00%. Alternatively, it can meet the following conditions: 0.08% ≤ Cao ≤ 2.00%. Alternatively, it can meet the following conditions: 0.09% ≤ Cao ≤ 1.50%.

[0038] In the contact lens product 100 of the present invention, the buffer solution 120 may further include at least one wetting agent, which is disposed in the buffer solution 120. The weight percentage concentration of the wetting agent is Cad, which is defined as the weight percentage concentration of any wetting agent, which may satisfy the following conditions: 0.001% ≤ Cad ≤ 1.00%. In this way, the moisturizing and lubricating effects of the contact lens 110 may be effectively provided. Alternatively, it may satisfy the following conditions: 0.01% ≤ Cad ≤ 0.50%.

[0039] In the contact lens product 100 of the present invention, the molecular weight of the curcumin derivative is Wmc, which may satisfy the following conditions: 400≤Wmc≤800. Thus, by the structural combination of the optimal curcumin derivative, the absorption effect of the curcumin derivative may be maintained and the monomer bonding efficiency may be improved. Alternatively, it may satisfy the following conditions: 410≤Wmc≤750. Alternatively, it may satisfy the following conditions: 420≤Wmc≤700. Alternatively, it may satisfy the following conditions: 430≤Wmc≤600. Alternatively, it may satisfy the following conditions: 450≤Wmc≤500.

[0040] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 280nm to 310nm is T2831, which can meet the following conditions: 50% ≤ T2831 ≤ 90%. Thus, by appropriately adjusting the amount of the curcumin derivative used, the absorption effect of the contact lens 110 in the UVB range can be effectively improved. Alternatively, it can meet the following conditions: 60% ≤ T2831 ≤ 88%. Alternatively, it can meet the following conditions: 70% ≤ T2831 ≤ 86%. Alternatively, it can meet the following conditions: 72% ≤ T2831 ≤ 80%.

[0041] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 310nm to 380nm is T3138, which can meet the following conditions: 60% ≤ T3138 ≤ 92%. Thus, by appropriately adjusting the amount of the curcumin derivative used, the absorption effect of the contact lens 110 in the UVA range can be effectively improved. Alternatively, it can meet the following conditions: 60% ≤ T3138 ≤ 85%. Alternatively, it can meet the following conditions: 75% ≤ T3138 ≤ 85%.

[0042] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 410nm to 460nm is T4146, which can meet the following conditions: 70% ≤ T4146 ≤ 90%. Thus, by appropriately adjusting the amount of the curcumin derivative used, the absorption effect of the contact lens 110 in the blue light range can be effectively improved. Alternatively, it can meet the following conditions: 75% ≤ T4146 ≤ 85%. Alternatively, it can meet the following conditions: 80% ≤ T4146 ≤ 90%.

[0043] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 460nm to 780nm is T4678, which can meet the following conditions: 90%≤T4678≤98%. Thus, by appropriately adjusting the amount of the curcumin derivative used, the high light transmittance effect of the contact lens 110 can be effectively maintained.

[0044] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the average transmittance of the contact lens 110 at a wavelength of 380nm to 780nm is T3878, which can meet the following conditions: 85%≤T3878≤98%. Thus, by appropriately adjusting the amount of the curcumin derivative used, the absorption and high light transmittance of the curcumin derivative of the contact lens 110 can be effectively balanced.

[0045] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 280nm to 310nm is BE2831, which can meet the following conditions: 4.0%≤BE2831≤50.0%. In this way, the absorption effect of the high-energy UVB light of the contact lens 110 can be effectively maintained. Alternatively, it can meet the following conditions: 5.0%≤BE2831≤50.0%. Alternatively, it can meet the following conditions: 5.0%≤BE2831≤40.0%. Alternatively, it can meet the following conditions: 6.0%≤BE2831≤30.0%. Alternatively, it can meet the following conditions: 7.5%≤BE2831≤20.0%. Alternatively, it can meet the following conditions: 10.0%≤BE2831≤50.0%.

[0046] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 310nm to 380nm is BE3138, which can meet the following conditions: 3.0%≤BE3138≤35.0%. In this way, the absorption effect of the high-energy UVA light of the contact lens 110 can be effectively maintained. Alternatively, it can meet the following conditions: 3.5%≤BE3138≤30.0%. Alternatively, it can meet the following conditions: 5.0%≤BE3138≤35.0%. Alternatively, it can meet the following conditions: 7.5%≤BE3138≤35.0%. Alternatively, it can meet the following conditions: 10.0%≤BE3138≤20.0%.

[0047] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 410nm to 460nm is BE4146, which can meet the following conditions: 1.0%≤BE4146≤30.0%. In this way, the absorption effect of the high-energy blue light of the contact lens 110 can be effectively maintained. Alternatively, it can meet the following conditions: 1.5%≤BE4146≤27.0%. Alternatively, it can meet the following conditions: 2.0%≤BE4146≤25.0%. Alternatively, it can meet the following conditions: 2.5%≤BE4146≤23.0%. Alternatively, it can meet the following conditions: 5.0%≤BE4146≤20.0%.

[0048] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 460nm to 780nm is BE4678, which can meet the following conditions: 0.5%≤BE4678≤5.0%. Thus, the high light transmittance of the contact lens 110 can be effectively maintained.

[0049] In the contact lens product 100 of the present invention, at least one day after the contact lens 110 is sterilized, the absorption blocking efficiency of the contact lens 110 at a wavelength of 380nm to 780nm is BE3878, which can meet the following conditions: 1.0%≤BE3878≤10.0%. In this way, the absorption of the curcumin derivative of the contact lens 110 and the high light transmittance effect can be effectively balanced.

[0050] In the contact lens product 100 of the present invention, the contact lens 110 may include at least two curcumin derivatives. Thus, the curcumin derivatives can be selected according to the desired color change effect, and a mixture of multiple curcumin derivatives can achieve different color change performances.

[0051] In the contact lens product 100 of the present invention, the contact lens 110 may further include at least one colorant. Thus, the color changing area of ​​the contact lens 110 of the present invention may include a mixed colorant of a curcumin derivative, so that the color changing area can achieve different color changes as needed. If the color changing area is designed to be smaller than the optical area in a ring shape, it will help to reduce stray light, so that it has a glare elimination effect when used in multifocal contact lenses that can reduce and control vision. Alternatively, if the color changing area is designed to be disc-shaped and covers the optical area, it can block strong light to achieve a light reduction effect like sunglasses. Alternatively, if the color changing area is further designed in the outer area of ​​the non-optical area, it has the effect of adjusting the appearance of the contact lens 110 to achieve an iris magnification effect.

[0052] Furthermore, in the contact lens product 100 of the present invention, the colorant of the contact lens 110 can form a pattern. The pattern can include text, numbers or patterns, can have directional and representative functions, and can produce effects such as identification marks, expiration date indications, direction identification, and indication of possible environmental hazards.

[0053] In the contact lens product 100 of the present invention, the contact lens 110 may include at least three lens layers, thereby preventing the colorant from leaking out of the contact lens 110 and reducing the chance of chemical substances contacting the eyes.

[0054] In the contact lens product 100 of the present invention, the contact lens product 100 is a one-day disposable product, and the contact lens product 100 may further include a light-proof package. Specifically, the curcumin derivative may lose its luminous effect over time after being exposed to light, so it is necessary to use it within the effective period when the curcumin derivative has the maximum activity to maintain the best light-shielding or light-reducing effect. The completely light-proof package can block light, protect and maintain the curcumin derivative in the contact lens 110, and help preserve it for a long time and maintain the best light-shielding or light-reducing effect.

[0055] The contact lens product 100 of the present invention is prepared by the following steps: (1) unmodified curcumin is synthesized into modified curcumin by a specific synthesis step. (2) modified curcumin is added to a specific formula monomer and uniformly mixed. (3) the monomer mixture is homogenized and then cured by UV / heat to form a contact lens 110. (4) the finished contact lens 110 is treated by a hydration step and stored in a buffer solution 120. (5) the sealed package containing the contact lens 110 and the buffer solution 120 is sterilized at a high temperature of 121° C. for at least 20 minutes to obtain the contact lens product 100 of the present invention.

[0056] In the contact lens product 100 of the present invention, the steps for measuring the transmittance of the contact lens 110 in a specific wavelength range are as follows: (1) The contact lens 110 is balanced in a standard solution. (2) The contact lens 110 and the standard solution are placed in a quartz plate, and the transmittance of the contact lens 110 is measured by an instrument under the conditions of a scanning accuracy of 1 nm and a scanning range of 200 nm to 800 nm.

[0057] The various technical features of the contact lens product of the present invention can be configured in combination to achieve corresponding effects.

[0058] The contact lenses of the present invention may have the functions of myopia correction, hyperopia correction, presbyopia correction, astigmatism correction, myopia control, corneal reshaping, etc.

[0059] The diopter of the contact lens described in the present invention is expressed as a D value, for example, the central diopter of the lens for correcting myopia is a negative value, and the central diopter of the lens for correcting hyperopia is a positive value. The aggravated myopia described in the present invention means that the myopia degree deepens, and the greater the absolute value of the negative diopter, such as -0.5D aggravated / deepened to -2.0D.

[0060] The surface shape of the contact lens described in the present invention may be spherical, flat or aspheric, based on the curved surface shape viewed through the center. The front surface of the contact lens described in the present invention refers to the surface away from the cornea of ​​the eyeball, and the back surface refers to the surface close to the cornea of ​​the eyeball.

[0061] The stable structure of the contact lens of the present invention may have a rotationally stable design, such as a lower thickened vertical weight design, a balanced design with thickened sides, an asymmetric balanced design, and a top and bottom thinned stable design.

[0062] The structure of the contact lens described in the present invention can be composed of at least two layers of lenses; wherein the colored contact lens can be composed of two layers, such as a lens body layer and a color layer; the colored contact lens can be composed of three layers, such as a lens body layer, a color layer and an anti-shedding protective layer; the colored contact lens can be composed of four layers, such as a lens body layer, a first color layer, a second color layer and an anti-shedding protective layer. The colored contact lens can be composed of five layers, such as a lens body layer, a first color layer, a second color layer, a third color layer and an anti-shedding protective layer. The colored contact lens can be another five-layer composition, such as a lens body layer, a first color layer, a separator layer, a second color layer and an anti-shedding protective layer.

[0063] The composition of the contact lens of the present invention comprises at least two monomers, at least one cross-linking agent, at least one diluent, at least one initiator, and optionally comprises an ultraviolet light absorber or a blue light absorber. Thus, the type and content of each component in the composition can be selected and adjusted, which helps to adjust the elastic coefficient of the contact lens and affect the hardness of the contact lens, thereby improving durability and stability, and can regulate the most appropriate water content of the contact lens to increase comfort and oxygen permeability. The composition comprises at least four monomers, at least two cross-linking agents, at least two diluents, at least one initiator, and optionally comprises an ultraviolet light absorber or a blue light absorber. Thus, a contact lens comprising both the first material and the second material can be prepared.

[0064] The hydrogel monomers of the contact lens of the present invention may include: 2-Hydroxyethyl methacrylate (HEMA), methacrylic acid (MAA), 2-methyl-2-acrylic acid-2,3-dihydroxypropyl (GMA), N-vinyl-2-pyrrolidinone (NVP), methyl methacrylate (MMA), N,N-dimethylacrylamide (DMAA), etc. This helps to maintain a moist, smooth, soft and comfortable moist feeling, allowing long-term wear and avoiding a foreign body sensation during wear.

[0065] The hydrogel for the contact lens of the present invention may be, but is not limited to, nonionic polymers classified as Group 1 contact lens materials by the U.S. Food and Drug Administration, i.e., nonionic polymers with low water content (less than 50 weight percent), such as Helfilcon A&B, Hioxifilcon B, Mafilcon, Polymacon, Tefilcon, Tetrafilcon A, etc. Alternatively, the hydrogel may be a nonionic polymer classified as Group 2 contact lens materials by the U.S. Food and Drug Administration, i.e., high water content (greater than 50 weight percent), such as Acofilcon A, Alfafilcon A, Hilafilcon B, Hioxifilcon A, Hioxifilcon B, Hioxifilcon D, Nelfilcon A, NesofilconA, Omafilcon A, and Samfilcon A, etc. Alternatively, the hydrogel may be an ionic polymer classified as Group 3 contact lens materials by the U.S. Food and Drug Administration, i.e., low water content (less than 50 weight percent), such as Deltafilcon A, etc. Alternatively, the hydrogel may be a Group 4 contact lens material classified by the U.S. Food and Drug Administration, i.e., an ionic polymer with a high water content (greater than 50 weight percent), such as Etafilcon A, Focofilcon A, Methafilcon A, Methafilcon B, Ocufilcon A, Ocufilcon B, Ocufilcon C, Ocufilcon D, Ocufilcon E, Phemfilcon A, Vifilcon A, etc.

[0066] The silicone hydrogel monomer of the contact lens of the present invention may be, but is not limited to, 2-hydroxyethyl methacrylate, glycerolmonomethacrylate, methacrylic acid, 3-methacryloyloxypropyltris(trimethylsilyloxy)silane, N-vinyl-2-pyrrolidinone, N,N-dimethyl acrylamide, (3-(3-methacryloxy-2-hydroxypropoxy)propylbis(trimethylsiloxy)methylsilane or (3-acryloxy-2-hydroxypropoxypropyl)terminated polydimethylsiloxane. In this way, the most appropriate monomer type can be selected, which helps to balance the parameters of durability, stability, comfort and oxygen permeability of the designed contact lenses. The oxygen permeability can be effectively improved to avoid red eyes, redness and swelling caused by corneal hypoxia, thereby providing comfort for long-term wear.

[0067] The silicone hydrogel of the contact lens described in the present invention may be, but is not limited to, contact lens materials classified as Group 5 by the United States Food and Drug Administration (USFDA), such as Balafilcon A, Comfilcon A, Efrofilcon A, Enfilcon A, Galyfilcon A, Lotrafilcon A, Lotrafilcon B, Narafilcon A, Narafilcon B, Senofilcon A, Delefilcon A, Somofilcon A, etc.

[0068] The contact lens product of the present invention may be composed of a contact lens body, a solution and a package. The contact lens body or the solution may contain: monomer, UV absorber, blue absorber, beneficial agents, wetting agent, dye, myopia control agent, acid and its conjugate base salt, base and its conjugate acid salt, anionic agent, cationic agent and other beneficial agents. The package of the present invention may be made by combining a plastic container and an aluminum foil cover. The plastic container may be made of polypropylene (PP), polystyrene (PS), polyethylene terephthalate (PET) or other plastic materials, and may also be made of biodegradable plastic, such as PLA (Polylactic Acid). Acid), PHA (polyhydroxyalkanoates) or other degradable plastics, etc. Biodegradable plastics can also be mixed with biodegradable plasticizers to achieve a modified or modified effect; the aluminum foil cover of the present invention can be a composite aluminum foil material with a plastic coating.

[0069] The initiator of the contact lens of the present invention may be, but is not limited to, 2-hydroxy-2-methyl-1-phenyl-1-propanone (2-hydroxy-2-methyl-propiophenone), thereby effectively achieving a high-efficiency polymerization reaction of the composition of the contact lens.

[0070] The crosslinking agent of the contact lens of the present invention may be, but is not limited to, ethylene glycol dimethacrylate or 1,1,1-trimethylol propanetrimethacrylate, thereby effectively achieving a good crosslinking effect between monomers and improving the stability and durability of the contact lens.

[0071] The diluent of the contact lens of the present invention can be polyethylene glycol 300, polyethylene glycol 600, polyethylene glycol 800, polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 4000, 1,4-butanediol, ethanol, isopropyl alcohol, glycerol or 1-hexanol. Thus, the elastic coefficient of the contact lens can be adjusted to improve the comfort of wearing the contact lens.

[0072] The ultraviolet (UV) absorber of the contact lens of the present invention may be, but is not limited to, 2-[3-(2H-benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate, 4-methacryloxy-2-hydroxybenzophenone, 2-phenylethylacrylate, 2-phenylethyl methacrylate, 2-(2'-hydroxy-5'-methacryloxyethylphenyl)-2H-benzotriazole or 2-(4-benzoyl-3-hydroxyphenoxy)ethyl acrylate. In this way, contact lenses can absorb high-energy UV light, thereby reducing the chance of retinal damage by UV light.

[0073] The blue light absorber of the contact lens of the present invention may be, but is not limited to, 4-(phenyldiazenyl)phenyl methacrylate. Thus, the contact lens can absorb high-energy blue light, thereby reducing the probability of retina being damaged by blue light.

[0074] The wetting agent for the contact lens of the present invention may include: 2-methacryloyloxyethylphosphorylcholine (MPC; 2-Methacryloyloxyphosphorylcholine), hyaluronic acid (Hyaluronic Acid), alginic acid (Alginic acid) or its salts and the like.

[0075] The pigments of the contact lenses of the present invention may include: anthocyanidin, beta-carotene, curcumin, luciferin, lutein, lycopene, phycobilin, phycoerythrim, phycocyanin, riboflavin (Vitamin B2), zeaxanthin, photochromic dyes, thermochromic dyes, etc., and their derivatives.

[0076] The beneficial agent of the contact lens of the present invention may include: antibiotics, bacteriostatic agents, antiviral agents, antifungal drugs, antiallergic agents, apomorphine, bromocriptine, dopamine receptor agonists, levodopa, or quinpirole, steroids, non-steroidal anti-inflammatory agents (NSAIDs), surfactants, miotics, enzyme inhibitors, anesthetics, vasoconstrictors, vitamins, antioxidants, nutrients, etc.

[0077] The antioxidants for the contact lenses of the present invention may be vitamin A, vitamin C, vitamin E, uric acid, carotenoid, flavonoids, resveratrol, selenomethionine, and the like.

[0078] The myopia control agent of the contact lens described in the present invention may include: ciliary muscle paralytics, mydriatics (mydriatics), selective / non-selective muscarinic receptor antagonists, etc., which have the effect of controlling, slowing down, delaying or preventing the aggravation of myopia. For example, by blocking the M-type muscarinic receptors of the parasympathetic nerves, the ciliary muscle that controls the pupil can be relaxed and paralyzed, thereby dilating the pupil. Such as Atropine (Atropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yltropate), Atropine sulphate, Cyclopentolate (2-(Dimethylamino)ethyl(1-hydroxycyclopentyl)(phenyl)acetate), Cyclopentolate HCl, Eucatropine (Eucatropine; 1,2,2,6-Tetramethyl-4-piperidinylhydroxy(phenyl)acetate), Homatropine (Homatropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-ylhydroxy(phenyl)acetate), Nuvenzepine, Phenylephrine hydrochloride HCl), Pirenzepine, Raceanisodamine, Rispenzepine, Scopolamine ((1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate), Scopolamine HBr, Telenzepine and Tropicamide (N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide), and their salts.

[0079] The various technical features of the contact lens product of the present invention can be configured in combination to achieve corresponding effects.

[0080] According to the above implementation modes, specific embodiments are proposed below and described in detail with reference to the drawings.

[0081] <First to Fourth Embodiments>

[0082] In the contact lens products of the first to fourth embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (1). For details of the curcumin derivatives of the first to fourth embodiments, please refer to Table 1.

[0083]

[0084] In the contact lens products of the first to fourth embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agent is hyaluronic acid (HA) and sodium alginate (SA). For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the first to fourth embodiments, please refer to Table 2.

[0085]

[0086] <Fifth to Eighth Embodiments>

[0087] In the contact lens products of the fifth to eighth embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (2). For details of the curcumin derivatives of the fifth to eighth embodiments, please refer to Table 3.

[0088]

[0089] In the contact lens products of the fifth to eighth embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the fifth to eighth embodiments, please refer to Table 4.

[0090]

[0091] Please refer to Figures 2 to 6 , Figure 2 1 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 280nm to 310nm. Figure 3 1 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 310nm to 380nm. Figure 4 1 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 410nm to 460nm. Figure 5 FIG. 2 is a graph showing the transmittance data of the fifth embodiment, the seventh embodiment and the first control group of the present invention at a wavelength of 460 nm to 780 nm. Figure 6The figure shows the transmittance data of the fifth embodiment, the seventh embodiment and the first control group at wavelengths of 380 nm to 780 nm of the present invention. In addition, in order to more clearly present the effect of the contact lens product of the present invention in overcoming the stability of the curcumin derivatives destroyed by high temperature and high pressure sterilization after adding an antioxidant to its buffer solution, a first control group not containing an antioxidant is further proposed for comparison with the fifth embodiment and the seventh embodiment, wherein the curcumin derivative of the first control group has a structure as shown in formula (2), and Ccu=0.05%.

[0092] The values ​​of T2831, T3138, T4146, T4678, and T3878 of the first control group, the fifth embodiment, and the seventh embodiment on the day before sterilization (day -1), on the day of sterilization (day 0), and ten days after sterilization (day 10) are recorded in Table 5.

[0093]

[0094] In addition, the values ​​of BE2831, BE3138, BE4146, BE4678, and BE3878 of the 5th and 7th embodiments on the day of sterilization and ten days after sterilization are further calculated based on the values ​​of T2831, T3138, T4146, T4678, and T3878 of the 1st control group and the 5th embodiment and the 1st control group and the 7th embodiment. In detail, the absorption blocking efficiency referred to in this specification is the percentage difference in the average transmittance of the contact lens product (C) containing the curcumin derivative and the contact lens product (nC) generally not containing the curcumin derivative within a specific wavelength range. For example, taking the average transmittance T2831 of the contact lens at a wavelength of 280nm to 310nm on the 10th day after sterilization as an example, the method of calculating its absorption blocking efficiency BE2831 at a wavelength of 280nm to 310nm is as follows:

[0095] BE2831=(|(C T2831 –nC T2831 )| / nC T2831 )×100,

[0096] Among them C T2831 is the average transmittance T2831 of the contact lens product containing curcumin derivatives at a wavelength of 280nm to 310nm, and nC T2831 The average transmittance T2831 of the contact lens product generally not containing curcumin derivatives at a wavelength of 280nm to 310nm is shown in Table 6. The values ​​of BE2831, BE3138, BE4146, BE4678, and BE3878 of the first control group and the fifth embodiment and the first control group and the seventh embodiment are shown in Table 6.

[0097]

[0098] Please refer to Figures 7 to 11 , Figure 7 1 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 280 nm to 310 nm. Figure 8 1 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 310nm to 380nm. Fig. 9 1 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 410nm to 460nm. Fig.10 is a graph showing the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 460nm to 780nm, and Fig.11 The figure shows the transmittance data of the eighth embodiment of the present invention and the second control group at wavelengths of 380 nm to 780 nm. In addition, in order to more clearly present the effect of the contact lens product of the present invention in overcoming the stability of the curcumin derivative destroyed by high temperature and high pressure sterilization after adding an antioxidant to its buffer solution, a second control group not containing an antioxidant is further proposed for comparison with the eighth embodiment, wherein the curcumin derivative of the second control group has a structure as shown in formula (2), and Ccu=0.05%.

[0099] The values ​​of T2831, T3138, T4146, T4678, and T3878 of the second control group and the eighth embodiment on the day before sterilization (day -1), the day of sterilization (day 0), ten days after sterilization (day 10), and seventeen days after sterilization (day 17) are recorded in Table 7.

[0100]

[0101] In addition, the values ​​of BE2831, BE3138, BE4146, BE4678, and BE3878 of the eighth example on the day of sterilization, ten days after sterilization, and seventeen days after sterilization are further calculated based on the values ​​of T2831, T3138, T4146, T4678, and T3878 of the second control group and the eighth example. The values ​​of BE2831, BE3138, BE4146, BE4678, and BE3878 of the second control group and the eighth example are recorded in Table 8.

[0102]

[0103] <9th to 12th embodiments>

[0104] In the contact lens products of the 9th to 12th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (3), and the details of the curcumin derivatives of the 9th to 12th embodiments are shown in Table 9.

[0105]

[0106] In the contact lens products of the 9th to 12th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 9th to 12th embodiments, please refer to Table 10.

[0107]

[0108] <13th to 16th embodiments>

[0109] In the contact lens products of the 13th to 16th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (4), and the details of the curcumin derivatives of the 13th to 16th embodiments are shown in Table 11.

[0110]

[0111] In the contact lens products of the 13th to 16th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 13th to 16th embodiments, please refer to Table 12.

[0112]

[0113] <17th to 20th embodiments>

[0114] In the contact lens products of the seventeenth to twentieth embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (5), and the details of the curcumin derivatives of the seventeenth to twentieth embodiments are shown in Table 13.

[0115]

[0116] In the contact lens products of the 17th to 20th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 17th to 20th embodiments, please refer to Table 14.

[0117]

[0118] <Examples 21 to 24>

[0119] In the contact lens products of the 21st to 24th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (6), and the details of the curcumin derivatives of the 21st to 24th embodiments are shown in Table 15.

[0120]

[0121] In the contact lens products of the 21st to 24th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 21st to 24th embodiments, please refer to Table 16.

[0122]

[0123] <Examples 25 to 28>

[0124] In the contact lens products of the 25th to 28th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (7), and the details of the curcumin derivatives of the 25th to 28th embodiments are shown in Table 17.

[0125]

[0126] In the contact lens products of the 25th to 28th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 25th to 28th embodiments, please refer to Table 18.

[0127]

[0128] <Examples 29 to 32>

[0129] In the contact lens products of the 29th to 32nd embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (8), and the details of the curcumin derivatives of the 29th to 32nd embodiments are shown in Table 19.

[0130]

[0131] In the contact lens products of the 29th to 32nd embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 29th to 32nd embodiments, please refer to Table 20.

[0132]

[0133] <Examples 33 to 36>

[0134] In the contact lens products of the 33rd to 36th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (9), and the details of the curcumin derivatives of the 33rd to 36th embodiments are shown in Table 21.

[0135]

[0136] In the contact lens products of the 33rd to 36th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 33rd to 36th embodiments, please refer to Table 22.

[0137]

[0138] <Examples 37 to 40>

[0139] In the contact lens products of the 37th to 40th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (10), and the details of the curcumin derivatives of the 37th to 40th embodiments are shown in Table 23.

[0140]

[0141] In the contact lens products of the 37th to 40th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 37th to 40th embodiments, please refer to Table 24.

[0142]

[0143] <Examples 41 to 44>

[0144] In the contact lens products of the 41st to 44th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (11), and the details of the curcumin derivatives of the 41st to 44th embodiments are shown in Table 25.

[0145]

[0146] In the contact lens products of the 41st to 44th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 41st to 44th embodiments, please refer to Table 26.

[0147]

[0148] <Examples 45 to 48>

[0149] In the contact lens products of the 45th to 48th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (12), and the details of the curcumin derivatives of the 45th to 48th embodiments are shown in Table 27.

[0150]

[0151] In the contact lens products of the 45th to 48th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 45th to 48th embodiments, please refer to Table 28.

[0152]

[0153] <Examples 49 to 52>

[0154] In the contact lens products of the 49th to 52nd embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (13), and for details of the curcumin derivatives of the 49th to 52nd embodiments, please refer to Table 29.

[0155]

[0156] In the contact lens products of the 49th to 52nd embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 49th to 52nd embodiments, please refer to Table 30.

[0157]

[0158] <Examples 53 to 56>

[0159] In the contact lens products of the 53rd to 56th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (14), and the details of the curcumin derivatives of the 53rd to 56th embodiments are shown in Table 31.

[0160]

[0161] In the contact lens products of the 53rd to 56th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 53rd to 56th embodiments, please refer to Table 32.

[0162]

[0163] <Examples 57 to 60>

[0164] In the contact lens products of the 57th to 60th embodiments, the curcumin derivative of the contact lens has a structure as shown in formula (15), and for details of the curcumin derivatives of the 57th to 60th embodiments, please refer to Table 33.

[0165]

[0166] In the contact lens products of the 57th to 60th embodiments, the antioxidant of the buffer solution is vitamin C, and the wetting agents are hyaluronic acid and sodium alginate. For the values ​​of Ccu, Cao, Cad, and Ccu / Cao of the 57th to 60th embodiments, please refer to Table 34.

[0167]

[0168] Although the present invention has been disclosed as above in the form of an implementation method, it is not intended to limit the present invention. Anyone skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention shall be determined by the scope of the attached patent application.

Claims

1. A contact lens product, characterized in that: Include: contact lenses; and a buffer solution in which the contact lens is stored, wherein the buffer solution comprises at least one antioxidant; The contact lens comprises at least one curcumin derivative, and the curcumin derivative has a structure as shown in formula (I) or formula (II): wherein at least one of R1 and R2 is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylate-2,3-dihydroxypropyl ester and hydrogen, and R1 and R2 are not both hydrogen; or wherein at least one of R3 and R4 is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylate-2,3-dihydroxypropyl ester and hydrogen, R5 is selected from the group consisting of hydroxyethyl methacrylate, methacrylic acid and 2-methyl-2-acrylate-2,3-dihydroxypropyl ester, and R3 and R4 are not both hydrogen; Wherein, the weight percentage concentration of the curcumin derivative in the contact lens is Ccu, and the weight percentage concentration of the antioxidant in the buffer solution is Cao, which satisfies the following conditions: 0.01≤Ccu / Cao≤10.

00.

2. The contact lens product according to claim 1, characterized in that: At least one of R1 and R2 in the formula (I) is hydroxyethyl methacrylate, or at least one of R3 and R4 in the formula (II) is hydroxyethyl methacrylate.

3. The contact lens product according to claim 1, characterized in that: R5 in the formula (II) is methacrylic acid or 2-methyl-2-acrylate-2,3-dihydroxypropyl ester.

4. The contact lens product according to claim 2, characterized in that: The weight percentage concentration of the curcumin derivative in the contact lens is Ccu, which satisfies the following conditions: 0.01%≤Ccu≤5.00%.

5. The contact lens product according to claim 4, characterized in that: The weight percentage concentration of the antioxidant in the buffer solution is Cao, which satisfies the following conditions: 0.05%≤Cao≤5.00%.

6. The contact lens product according to claim 5, characterized in that: The buffer solution further comprises at least one wetting agent, the weight percentage concentration of the wetting agent is Cad, which satisfies the following conditions: 0.001%≤Cad≤1.00%.

7. The contact lens product according to claim 6, characterized in that: The molecular weight of the curcumin derivative is Wmc, which satisfies the following conditions: 400≤Wmc≤800.

8. The contact lens product according to claim 1, characterized in that: At least one day after the contact lens is sterilized, the average transmittance of the contact lens at a wavelength of 280nm to 310nm is T2831, which meets the following conditions: 50％≤T2831≤90％。 9. The contact lens product according to claim 8, characterized in that: At least one day after the contact lens is sterilized, the average transmittance of the contact lens at a wavelength of 310nm to 380nm is T3138, which meets the following conditions: 60％≤T3138≤92％。 10. The contact lens product according to claim 9, characterized in that: At least one day after the contact lens is sterilized, the average transmittance of the contact lens at a wavelength of 410nm to 460nm is T4146, which meets the following conditions: 70％≤T4146≤90％。 11. The contact lens product according to claim 1, characterized in that: At least one day after the contact lens is sterilized, the absorption blocking efficiency of the contact lens at a wavelength of 280nm to 310nm is BE2831, which meets the following conditions: 4.0%≤BE2831≤50.0%.

12. The contact lens product according to claim 11, characterized in that: At least one day after the contact lens is sterilized, the absorption blocking efficiency of the contact lens at a wavelength of 310nm to 380nm is BE3138, which meets the following conditions: 3.0%≤BE3138≤35.0%.

13. The contact lens product according to claim 12, characterized in that: At least one day after the contact lens is sterilized, the absorption barrier efficiency of the contact lens at a wavelength of 410nm to 460nm is BE4146, which meets the following conditions: 1.0%≤BE4146≤30.0%.

14. The contact lens product according to claim 4, characterized in that: The contact lens comprises at least a dicurcumin derivative.

15. The contact lens product according to claim 4, characterized in that: The contact lens further comprises at least one pigment.

16. The contact lens product according to claim 15, characterized in that: The contact lens comprises at least three lens layers.

17. The contact lens product according to claim 16, wherein: The at least one colorant forms a pattern.

18. The contact lens product according to claim 1, characterized in that: The contact lens product is a daily disposable product, and the contact lens product further comprises: Protect from light.

Images